Professional Documents
Culture Documents
Cancer Treatments and Their Side Effects Are Associated With Aggravation of Insomnia Results of A Longitudinal Study
Cancer Treatments and Their Side Effects Are Associated With Aggravation of Insomnia Results of A Longitudinal Study
BACKGROUND: Insomnia affects between 30% to 60% of patients with cancer but to the authors’ knowledge little is known regard-
ing factors associated with its development. It has been postulated that adjuvant cancer treatments and their side effects could trig-
ger sleep disturbances in this population but empirical evidence is lacking. The goal of the current study was to assess, separately in
patients with breast and prostate cancer, the effect of adjuvant treatments on the evolution of insomnia symptoms and the mediating
role of somatic symptoms. METHODS: As part of a population-based epidemiological study, patients with breast cancer (465
patients) and prostate cancer (263 patients) completed at baseline (perioperative period) and 2 months, 6 months, 10 months, 14
months, and 18 months later the Insomnia Severity Index (ISI) and a questionnaire assessing various somatic symptoms. RESULTS: In
patients with breast cancer, radiotherapy (overall effect) and chemotherapy (at 2 months), but not hormone therapy, were associated
with increased insomnia severity, whereas androgen deprivation therapy was related to increased insomnia in patients with prostate
cancer. In patients with breast cancer, the effect of chemotherapy and radiotherapy on insomnia was found to be significantly medi-
ated by a variety of somatic symptoms, whereas night sweats had a particularly marked mediating role for hormone therapy, both
in patients with breast and prostate cancer. CONCLUSIONS: The findings of the current study indicate that cancer treatments
and their side effects contribute to the aggravation of insomnia symptoms. Side effects of cancer treatments should be monitored
more closely and managed as effectively as possible to prevent the occurrence or aggravation of insomnia. Cancer 2015;000:000-
000. VC 2015 American Cancer Society.
INTRODUCTION
Insomnia is a common problem in patients with cancer. Although insomnia is highly prevalent before any treatment is
administered,1 longitudinal data suggest that there are factors occurring during the cancer care trajectory that trigger its de-
velopment. A recent population-based epidemiological study revealed that insomnia affected up to 59% of patients during
the perioperative period.2 However, 14.4% of patients had a first incidence and 19.5% had a recurrence of insomnia
symptoms during the course of the study, for a total incidence rate of 31.8%.3
Although causes of insomnia comorbid with cancer are most likely multifaceted,4,5 it has been postulated that ad-
juvant treatments play a significant role.6,7 To the best of our knowledge, only a few longitudinal studies to date have
focused on this issue. Although lack of an association has also been noted,8 receiving chemotherapy has been found to
predict an increase in sleep disturbance during the cancer care trajectory.1,9 Two studies of patients with breast cancer
found that radiotherapy was associated with a temporary augmentation of sleep difficulties10,11 and one study revealed
that intensity-modulated radiotherapy for the treatment of nasopharyngeal cancer was associated with an increased
rate of clinically significant sleep impairments.12 In patients with prostate cancer, the introduction of androgen depri-
vation therapy was found to be related to increased insomnia symptoms.13 Hence, it would appear that all 3 of these
adjuvant treatments can increase the risk of insomnia, although studies disentangling their respective effects are
lacking.
We wish to acknowledge the important contribution of Julie Villa, Aude Caplette-Gingras, Marie-Solange Bernatchez, Val erie Tremblay, Lucie Casault, Caroline
Desautels, Genevi eve Dumont, Dave Flanagan, Nathalie Gagnon, Catherine Gonthier, Geneviève Laurent, Marie-Eve Le May, Julie Maheux, Marie-Esther Paradis,
Sylvie Perron, Julie Roy, Sophie Ruel, Elaine Th
eriault, Claudia Trudel-Fitzgerald, and Maude Villeneuve who were involved in the recruitment and assessment of
the participants or the data entry and the study coordination, as well as the participants who volunteered their time for this study.
DOI: 10.1002/cncr.29244, Received: July 3, 2014; Revised: October 16, 2014; Accepted: December 17, 2014, Published online Month 00, 2015 in Wiley Online
Library (wileyonlinelibrary.com)
There are several plausible mechanisms through 1519 were excluded and 715 refused to participate in the
which cancer treatments could lead to sleep disturbances. study, thus giving a participation rate for the larger study
Although other mechanisms are possible (eg, anticipatory of 57.4% (962 patients; for a detailed flowchart see the
anxiety, behavioral changes such as day napping that study by Savard et al3). For the purpose of the current
impair circadian rhythms, or chemotherapy-induced analysis, only the 2 larger subgroups of patients could be
inflammation),4,14-16 adjuvant treatments can also induce included (ie, patients with breast cancer [465 patients]
sleep disturbances through some of their negative side and prostate cancer [263 patients]) (Table 1).
effects. Nocturnal hot flashes (due to chemotherapy and
hormone therapy17), urinary incontinence (eg, due to Study Design
radiotherapy to the urogenital area), and gastrointestinal This study used a prospective longitudinal design com-
symptoms (eg, chemotherapy-induced nausea) as well as prising 6 time points: baseline (perioperative phase; T1)
pain (eg, associated with the use of aromatase inhibitors in and 2 months (T2), 6 months (T3), 10 months (T4), 14
both men and women16) are all very likely to negatively months (T5), and 18 months (T6). Overall, 72.7% of the
affect sleep quality.6,7,18 However, to our knowledge, very patients with breast cancer (338 patients) and 69.6% of
little research data are available to help delineate their role patients with prostate cancer (183 patients) completed all
in precipitating insomnia comorbid with cancer. 6 assessments (Mean (M) 5 5.2).
The goals of this secondary analysis of a previous ep-
Measures
idemiological study by Savard et al2,3 were to assess, sepa-
Demographics, health behaviors, and cancer
rately in individuals with breast and prostate cancer, 1) the characteristics
effect of adjuvant treatments on the evolution of insomnia Demographics, medical comorbidity, medication use,
symptoms and 2) to what extent somatic symptoms medi- and health behaviors (smoking status, alcohol and caffeine
ated the relationship between adjuvant treatments and use, and physical activity) were collected using a question-
insomnia symptoms. It was hypothesized that all adjuvant naire. Cancer-related data (eg, cancer site and stage and
treatments would be associated with increased insomnia adjuvant treatments received) were obtained from the
through the mediating effect of somatic symptoms. patient’s medical record.
Abbreviations: AC, cyclophosphamide and doxorubicin; AJCC, American Joint Committee on Cancer; FEC, 5-fluorouracil, epirubicin, and cyclophosphamide;
SD, standard deviation.
a
Patients with stage IV cancer did not have distant metastases.
b
Some patients did not receive any adjuvant treatment whereas others received >1 treatment during the study.
c
The percentages computed over the number of users.
d
Patients could have received >1 treatment.
e
The percentage of patients displaying a clinical level of insomnia (Insomnia Severity Index 8).
Original Article
Procedure
At each time point, participants were given a battery of
self-report scales including the ISI and the Physical Symp-
toms Questionnaire that they had to complete within the
next week and mail back. More details on the procedure
are available elsewhere.2
Statistical Analyses
Descriptive and inferential statistics were conducted using
SAS statistical software (version 9.3; SAS Institute Inc,
Cary, NC).23 The alpha level was fixed at 5% (2-tailed) for
all inferential tests. All participants with at least 1 available
Figure 1. Percentage of patients with (a) breast cancer and
time point on the main outcome (ISI) were included in the (b) prostate cancer exposed to each treatment since the last
analyses (728 participants) and no data imputation was per- assessment at each time point are shown.
effect. The percentage of the total effect explained by the nificant time effect (F(2,760) 5 9.77; P<.001) and a sig-
mediated (indirect) effect was computed as the ratio of the nificant and unique radiotherapy effect (F(1,345) 5 3.84;
mediation standard coefficient on the standard coefficient P 5 .05), but no significant main effect for chemotherapy
for the total treatment effect. A mediation was considered (F(1,190) 5 0.79; P 5 .38) or hormone therapy
a total mediation when only the mediation (indirect) (F(1,175) 5 0.06; P 5 .80) after controlling for the effect
effect was statistically significant, whereas a partial media- of the other 2 treatments. However, simple effects demon-
tion was determined when both mediation and directs strated that women receiving chemotherapy had signifi-
effects were significant. cantly greater ISI scores at T2 than those not receiving this
treatment (M of 10.6 vs 9.1; F(1,760) 5 5.29 [P 5 .02])
(Fig. 3a), which corresponds to their peak exposure to
RESULTS
chemotherapy (Fig. 1a). Overall, the exposure to radio-
Objective 1: Effect of Adjuvant Treatments on
therapy was associated with significantly higher ISI scores
the Evolution of Insomnia Severity
Breast cancer
throughout the study (M of 9.0 vs 8.4) (Fig. 3b). No treat-
In participants with breast cancer, the results of a normal ment 3 time interaction was found to be statistically sig-
linear mixed model conducted on ISI scores revealed a sig- nificant (P 5 .23 for chemotherapy, P 5 .87 for
radiotherapy, and P 5 .66 for hormone therapy).
Prostate cancer
The mixed model analysis conducted among participants
with prostate cancer revealed a significant main effect for
hormone therapy (F(1,9) 5 5.01; P 5 .05) but no signifi-
cant time effect (F(1,610) 5 0.62; P 5 .60) or interaction
(F(1,610) 5 0.83; P 5 .48). Overall, participants
reported significantly higher ISI scores throughout the
study when exposed to hormone therapy (M of 7.3 vs 5.4)
(Fig. 3d). In addition, simple effects revealed that patients
receiving hormone therapy had significantly greater ISI
scores at T4 (P 5 .03), T5 (P 5 .04), and T6 (P 5 .03),
which corresponds to the peak exposure to hormone ther-
apy in that group (Fig. 1b).
Figure 3. Adjusted Insomnia Severity Index (ISI) scores are shown for participants exposed or not to each cancer treatment since
the time of the last assessment. Only time points with at least 10 participants exposed are shown: (a) chemotherapy in breast
cancer, (b) radiotherapy in breast cancer, (c) hormone therapy in breast cancer, and (d) hormone therapy in prostate cancer.
TABLE 2. Concurrent and Longitudinal Mediational Effects of Symptoms on the Relationship Between
Treatment and Insomnia, According to Treatment and Cancer Type
Abbreviations: %, percentage of the total relation accounted for by the mediation effect; NS, not significant; P, partial mediation; T, total mediation; Z0 , Z-prime
statistic for the alpha 3 beta mediation test.
a
P <.01.
b
P <.05.
The lagged (longitudinal) effect of chemotherapy on effect [partial mediation]) and night sweats (14.9% of the
insomnia was significantly mediated by headache (73.0% total effect). The lagged radiotherapy effect was signifi-
of the total effect), digestive symptoms (20.2% of the total cantly mediated by headache (35.9% of the total effect)
effect), and nausea (14.3% of the total effect). The con- and nausea (3.9% of the total effect). Finally, the concur-
current effect of radiotherapy on insomnia symptoms was rent effect of hormone therapy on ISI scores was signifi-
significantly mediated by dyspnea (19.8% of the total cantly mediated by night sweats (100% of the total
effect), digestive symptoms (21.8% of the total effect), matic symptoms suggest that this negative impact is sig-
and headache (15.4% of the total effect), whereas the nificantly due to its side effects, in particular headache,
lagged effect was significantly mediated by digestive nausea and digestive symptoms, urination, and night
symptoms only (36.7% of the total effect). sweats.
Some chemotherapeutic agents can induce headache
Prostate cancer (eg, 5-fluorouracil) and a bidirectional relationship
Again, concurrent effects were more frequent (4 signifi- between headache and insomnia appears to exist.31
cant effects from 4 tests) than lagged effects (only 1 Indeed, the discomfort associated with headache may
significant effect). The concurrent effect of androgen de- interfere with falling and staying asleep throughout the
privation therapy on symptoms of insomnia was signifi- night, but disturbed sleep can also cause headache. A dele-
cantly mediated by night sweats (48.6% of the total terious impact of chemotherapy-induced nausea and di-
effect), dyspnea (18.0% of the total effect), urinary gestive symptoms on sleep has already been shown.32
symptoms (16.6% of the total effect), and pain (13.8% of However, it should be noted that this effect could also be
the total effect), whereas the lagged effect was signifi- explained by the use of antiemetic medications that can al-
cantly mediated by night sweats only (45.8% of the total ter sleep as well (eg, dexamethasone33). Increased urina-
effect). tion, another possible side effect of chemotherapy, was
associated with greater severity of insomnia, which is con-
DISCUSSION sistent with an increasing body of literature indicating a
The current longitudinal study assessed, within the con- link between nocturia and poor sleep in the general popu-
text of breast and prostate cancer, the role of adjuvant lation.34 Finally, findings regarding night sweats are con-
treatments in the evolution of insomnia symptoms over sistent with studies performed within the context of breast
an 18-month period and the mediating role of somatic cancer using objective measures (polysomnography and
symptoms potentially caused by these treatments. In sternal skin conductance) supporting a concurrent associ-
patients with breast cancer, the findings indicated that ation between nocturnal hot flashes and various sleep
chemotherapy (at T2) and radiotherapy (overall effect), impairments.35,36
but not hormone therapy, were associated with an aggra- In the subsample of patients with breast cancer,
vation of insomnia symptoms after controlling for the radiotherapy was found to be associated with a signifi-
effect of the other 2 treatments. In this group, the effect of cantly increased severity of insomnia overall. The strong-
chemotherapy and radiotherapy on insomnia levels was est mediating effect was found for headache. Because
significantly mediated by a variety of somatic symptoms irradiating the breast is not likely to induce headache, this
likely to be their side effects. Although hormone therapy may indicate an inverse relationship in which headache is
was not found to be associated with a significant exacerba- induced by insomnia. Other significant mediating effects
tion of insomnia symptoms in that group, its effect was were noted for dyspnea, night sweats, and nausea, but
significantly mediated by night sweats. In patients with they explained a smaller percentage of the total effect.
prostate cancer, androgen deprivation therapy was consis- Overall, somatic symptoms, at least those assessed in the
tently associated with increased insomnia symptoms, an current study, appear to explain to a lesser extent the rela-
effect that was strongly mediated by night sweats. Given tionship between radiotherapy and insomnia in patients
that nearly all mediating effects in both groups were total with breast cancer. Future studies should investigate the
mediations, this suggests that somatic symptoms explain a possible mediating role of fatigue. Fatigue is significantly
major percentage of the relationship between cancer treat- correlated with insomnia within the context of radiother-
ments and insomnia. apy,37 and our previous findings using the same sample
In patients with breast cancer, chemotherapy was revealed that fatigue was a significant predictor of
associated with increased insomnia symptoms, an effect insomnia.38
that was significant at T2 when 51.3% of the women were Hormone therapy also was found to be associated
receiving this treatment. These results are consistent with with significantly greater insomnia scores, but only in
some evidence pointing to a deleterious effect of chemo- men with prostate cancer. In that group, the effect was sig-
therapy on sleep.1,27-29 Although other mechanisms are nificant overall and at each time point, except T3, when
possible (eg, psychological reaction, disruption of circa- only 6.9% of patients received this treatment. Although
dian rhythms, or immune response4,30), the current analyses revealed a small mediating role of other symp-
results supporting the mediating role of a variety of so- toms (ie, dyspnea, urinary symptoms, and pain), the most
influential mediator was night sweats. Findings of the cur- FUNDING SUPPORT
rent study are consistent with those of another recent lon- Supported by a grant from the Canadian Institutes of Health
gitudinal study that demonstrated a deleterious effect of Research (MOP-69073).
androgen deprivation therapy for prostate cancer on
insomnia levels through the mediating role of night sweats CONFLICT OF INTEREST DISCLOSURES
and hot flashes.13 It is interesting to note that even though Dr. Morin has served as consultant for Merck, Novartis, and
Valeant and received research support from Novartis for work per-
hormone therapy was not associated with significantly
formed outside of the current study.
increased insomnia in patients with breast cancer in the
current study, night sweats explained 100% of the rela- REFERENCES
tionship between this treatment and insomnia, thereby 1. Van Onselen C, Paul SM, Lee K, et al. Trajectories of sleep disturb-
emphasizing the importance of this symptom as a risk fac- ance and daytime sleepiness in women before and after surgery for
tor for insomnia in this group as well. The finding that breast cancer. J Pain Symptom Manage. 2013;45:244-260.
2. Savard J, Villa J, Ivers H, Simard S, Morin CM. Prevalence, natural
hormone therapy was not associated with a significant course, and risk factors of insomnia comorbid with cancer over a 2-
exacerbation of insomnia in patients with breast cancer is month period. J Clin Oncol. 2009;27:5233-5239.
surprising but may be due to some ceiling effect. Indeed, 3. Savard J, Ivers H, Villa J, Caplette-Gingras A, Morin CM. Natural
course of insomnia comorbid with cancer: an 18-month longitudinal
women with breast cancer had already, on average, clinical study. J Clin Oncol. 2011;29:3580-3586.
levels of insomnia before receiving hormone therapy (at 4. Palesh O, Peppone L, Innominato PF, et al. Prevalence, putative
mechanisms, and current management of sleep problems during
T2), thus leaving less room for further aggravation of their chemotherapy for cancer. Nat Sci Sleep. 2012;4:151-162.
symptoms because of its introduction. 5. Ancoli-Israel S, Savard J. Sleep and fatigue in cancer patients. In:
The current study is characterized by several Kryger MH, Roth T, Dement WC, eds. Principles and Practice of
Sleep Medicine. St Louis, MO: Elsevier Saunders; 2011:1416-1421.
strengths, including the use of a large population-based 6. Savard J, Savard MH. Insomnia and cancer: prevalence, nature, and
sample and of a longitudinal design with 6 time points nonpharmacologic treatment. Sleep Med Clin. 2013;8:373-387.
over the entire cancer care trajectory. Given that treatment 7. Yue HJ, Dimsdale JE. Management of specific symptoms: sleep and
cancer. In: Holland JC, Breitbart W, Jacobsen PB, et al, eds. Psy-
regimens and side effect profiles may vary across cancers, chooncology. 2nd ed. New York: Oxford University Press; 2010:
the separate investigation of the most common cancer 258-269.
8. Sanford SD, Wagner LI, Beaumont JL, Butt Z, Sweet JJ, Cella D.
types is also a strength. One limitation is the relatively Longitudinal prospective assessment of sleep quality: before, during,
large time frame between the study measurements, thus and after adjuvant chemotherapy for breast cancer. Support Care
Cancer. 2013;21:959-967.
making causal inferences difficult. Indeed, participants
9. Liu L, Fiorentino L, Natarajan L, et al. Pre-treatment symptom clus-
were considered to be exposed to a particular treatment if ter in breast cancer patients is associated with worse sleep, fatigue
they had received it since the time of the last assessment. and depression during chemotherapy. Psychooncology. 2009;18:187-
194.
Given the large intervals between time points (2-4 10. Omne-Ponten M, Holmberg L, Burns T, Adami HO, Bergstrom R.
months), this means that treatments may have ended days Determinants of the psycho-social outcome after operation for breast
and even weeks before insomnia (and somatic symptoms) cancer: results of a prospective comparative interview study following
mastectomy and breast conservation. Eur J Cancer. 1992;28A:1062-
was measured, thus potentially weakening the strength of 1067.
the association between treatments and the severity of 11. Wengstrom Y, Haggmark C, Strander H, Forsberg C. Perceived
symptoms and quality of life in women with breast cancer receiving
insomnia. This may also explain why concurrent associa- radiation therapy. Eur J Oncol Nurs. 2000;4:78-88.
tions were more frequent than longitudinal ones. Finally, 12. Mo YL, Li L, Qin L, et al. Cognitive function, mood, and sleep
given the large variety of treatments received in the cur- quality in patients treated with intensity-modulated radiation therapy
for nasopharyngeal cancer: a prospective study. Psychooncology. 2014;
rent study sample, the analyses could not assess the differ- 23:1185-1191.
ential impact of each type of chemotherapy regimen and 13. Savard J, Hervouet S, Ivers H. Prostate cancer treatments and their
side effects are associated with increased insomnia. Psychooncology.
hormone therapy. 2013;22:1381-1388.
Although the etiology of insomnia comorbid with 14. Levin TT, Alici Y. Psychiatric disorders: anxiety disorders. In: Hol-
cancer is most likely multifactorial, the results of the land JC, Breitbart W, Jacobsen PB, et al, eds. Psychooncology. 2nd
ed. New York: Oxford University Press; 2010:324-331.
current study suggest that adjuvant cancer treatments 15. Liu L, Marler MR, Parker BA, et al. The relationship between fa-
are associated with increased severity of insomnia through tigue and light exposure during chemotherapy. Support Care Cancer.
2005;13:1010-1017.
the mediating effect of their side effects. The results of
16. Park JY, Lee SK, Bae SY, et al. Aromatase inhibitor-associated mus-
the current study highlight the importance of the appro- culoskeletal symptoms: incidence and associated factors. J Korean
priate management of the side effects of cancer treatments Surg Soc. 2013;85:205-211.
17. Buijs C, de Vries EG, Mourits MJ, Willemse PH. The influence of
to prevent the occurrence or aggravation of sleep endocrine treatments for breast cancer on health-related quality of
difficulties. life. Cancer Treat Rev. 2008;34:640-655.
18. Savard J. Insomnia. In: Davis MP, Feyer P, Ortner P, Zimmermann day variation and relationships among symptom changes. Ann Behav
C, eds. Supportive Oncology. 1st ed. Philadelphia: Elsevier Saunders; Med. 2011;42:321-333.
2011:187-199. 30. Wood LJ, Weymann K. Inflammation and neural signaling: etiologic
19. Morin CM. Insomnia: Psychological Assessment and Management. mechanisms of the cancer treatment-related symptom cluster. Curr
New York: The Guilford Press; 1993. Opin Support Palliat Care. 2013;7:54-59.
20. Savard MH, Savard J, Simard S, Ivers H. Empirical validation of the 31. Tran DP, Spierings EL. Headache and insomnia: their relation
Insomnia Severity Index in cancer patients. Psychooncology. 2005;14:
reviewed. Cranio. 2013;31:165-170.
429-441.
21. Portenoy RK, Thaler HT, Kornblith AB, et al. The Memorial 32. Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J. Effect of
Symptom Assessment Scale: an instrument for the evaluation of postchemotherapy nausea and vomiting on health-related quality of
symptom prevalence, characteristics and distress. Eur J Cancer. 1994; life. The Quality of Life and Symptom Control Committees of the
30A:1326-1336. National Cancer Institute of Canada Clinical Trials Group. Support
22. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd Care Cancer. 1997;5:307-313.
ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988. 33. Ling MH, Perry PJ, Tsuang MT. Side effects of corticosteroid ther-
23. SAS Institute Inc. SAS/STAT 9.3 User’s Guide. Cary, NC: SAS apy: psychiatric aspects. Arch Gen Psychiatry. 1981;38:471-477.
Institute Inc; 2011. 34. Bliwise DL, Friedman L, Hernandez B, Zeitzer JM, Kushida CA,
24. Frigon JY, Laurencelle L. Analysis of covariance: a proposed algo- Yesavage JA. Nocturia reported in nightly sleep diaries: common
rithm. Educ Psychol Meas. 1993;53:1-18. occurrence with significant implications? Health Psychol. 2014;33:
25. MacKinnon DP. Longitudinal mediation models. In: MacKinnon 1362-1365.
DP, ed. Introduction to Statistical Mediation Analysis. New York: 35. Savard J, Davidson JR, Ivers H, et al. The association between noc-
Lawrence Erlbaum Associates, Taylor & Francis Group; 2008:193- turnal hot flashes and sleep in breast cancer survivors. J Pain Symp-
236. tom Manage. 2004;27:513-522.
26. MacKinnon DP, Lockwood CM, Hoffman JM, West SG, Sheets V.
A comparison of methods to test mediation and other intervening 36. Savard MH, Savard J, Caplette-Gingras A, Ivers H, Bastien C. Rela-
tionship between objectively recorded hot flashes and sleep distur-
variable effects. Psychol Methods. 2002;7:83-104.
bances among breast cancer patients: investigating hot flash
27. Savard J, Liu L, Natarajan L, et al. Breast cancer patients have pro-
gressively impaired sleep-wake activity rhythms during chemother- characteristics other than frequency. Menopause. 2013;20:997-1005.
apy. Sleep. 2009;32:1155-1160. 37. Donovan KA, Jacobsen PB. Fatigue, depression, and insomnia: evi-
28. Chen ML, Yu CT, Yang CH. Sleep disturbances and quality of life dence for a symptom cluster in cancer. Semin Oncol Nurs. 2007;23:
in lung cancer patients undergoing chemotherapy. Lung Cancer. 127-135.
2008;62:391-400. 38. Trudel-Fitzgerald C, Savard J, Ivers H. Which symptoms come first?
29. Jim HS, Small B, Faul LA, Franzen J, Apte S, Jacobsen PB. Fatigue, Exploration of temporal relationships between cancer-related symp-
depression, sleep, and activity during chemotherapy: daily and intra- toms over an 18-month period. Ann Behav Med. 2013;45:329-337.